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Abstract
Peritoneal metastasis is a common sign of advanced 
tumor stage, tumor progression or tumor recurrence in 
patients with colorectal cancer. Due to the improvement 
of systemic chemotherapy, the development of targeted 
therapy and the introduction of additive treatment options 
such as cytoreductive surgery (CRS) and hyperthermic 
intraperitoneal chemotherapy (HIPEC), the therapeutic 
approach to peritoneal metastatic colorectal cancer 
(pmCRC) has changed over recent decades, and patient 
survival has improved. Moreover, in contrast to palliative 
systemic chemotherapy or best supportive care, the 
inclusion of CRS and HIPEC as inherent components 
of a multidisciplinary treatment regimen provides a 
therapeutic approach with curative intent. Although CRS 
and HIPEC are increasingly accepted as the standard 
of care for selected patients and have become part of 
numerous national and international guidelines, the 
individual role, optimal timing and ideal sequence of 
the different systemic, local and surgical treatment 
options remains a matter of debate. Ongoing and future 
randomized controlled clinical trials may help clarify the 
impact of the different components, allow for further 
improvement of patient selection and support the standar­
dization of oncologic treatment regimens for pmCRC. 
The addition of further therapeutic options such as neo­
adjuvant intraperitoneal chemotherapy or pressurized 
intraperitoneal aerosol chemotherapy, should be investig­
ated to optimize therapeutic regimens and further improve 
the oncological outcome. 
Key words: Peritoneal metastasis; Colorectal cancer; 
Systemic chemotherapy; Intraperitoneal chemotherapy; 
Cytoreductive surgery
© The Author(s) 2016. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Beyond diverse systemic, interventional and 
Therapeutic options for peritoneal metastasis arising from 
colorectal cancer
Gabriel Glockzin, Hans J Schlitt, Pompiliu Piso
Gabriel Glockzin, Department of Surgery, Staedtisches Klinikum 
Muenchen GmbH, Klinikum Bogenhausen, 81925 Munich, Germany
Hans J Schlitt, Department of Surgery, University Hospital 
Regensburg, 93053 Regensburg, Germany
Pompiliu Piso, Department of Surgery, Hospital of the Order of 
St. John of God, 93049 Regensburg, Germany
Author contributions: Glockzin G drafted the manuscript; 
Schlitt HJ and Piso P revised the manuscript; all authors read and 
approved the final manuscript.
Conflict­of­interest statement: All authors declare that they 
have no conflicts of interest.
Open­Access: This article is an open-access article which was 
selected by an in-house editor and fully peer-reviewed by external 
reviewers. It is distributed in accordance with the Creative 
Commons Attribution Non Commercial (CC BY-NC 4.0) license, 
which permits others to distribute, remix, adapt, build upon this 
work non-commercially, and license their derivative works on 
different terms, provided the original work is properly cited and 
the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/
Manuscript source: Invited manuscript
Correspondence to: Gabriel Glockzin, MD, FEBS, Department 
of Surgery, Staedtisches Klinikum Muenchen GmbH, Klinikum 
Bogenhausen, Englschalkinger Str. 77, 81925 Munich, 
Germany. gabriel.glockzin@klinikum-muenchen.de 
Telephone: +49-89-92702011
Fax: +49-89-92702016
Received: March 29, 2016
Peer­review started: April 4, 2016
First decision: May 17, 2016
Revised: June 22, 2016
Accepted: July 11, 2016
Article in press: July 13, 2016
Published online: August 6, 2016
TOPIC HIGHLIGHT
Submit a Manuscript: http://www.wjgnet.com/esps/
Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx
DOI: 10.4292/wjgpt.v7.i3.343
343 August 6, 2016|Volume 7|Issue 3|WJGPT|www.wjgnet.com
World J Gastrointest Pharmacol Ther 2016 August 6; 7(3): 343-352
ISSN 2150-5349 (online)
© 2016 Baishideng Publishing Group Inc. All rights reserved.
2016 Colorectal Cancer: Global view
surgical palliative treatment options for peritoneal meta­
stasis arising from colorectal cancer, the combination 
of systemic chemotherapy, cytoreductive surgery and 
hyperthermic intraperitoneal chemotherapy provides a 
therapeutic approach with curative intent for selected 
patients. Nevertheless, the treatment regimens, the 
sequence of therapy and the impact of the different 
components of the multidisciplinary treatment concept 
on clinical and oncological outcomes remain a matter 
of debate. Moreover, the addition of further therapeutic 
options to the existing treatment regimens might allow 
for higher complete resection rates and improved survival 
rates.
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INTRODUCTION
Colorectal cancer (CRC) remains one of the leading 
causes of cancer-related death worldwide[1]. Peritoneal 
metastasis (PM) is common in patients with advanced 
stage primary and recurrent colorectal cancer[2,3]. The 
natural course of this disease is associated with poor 
prognosis and led to a mean overall survival of 5.2 mo in 
the prospective European multicenter EVOCAPE I study 
(n = 118)[4]. A retrospective analysis of 3000 patients 
with pmCRC reported a median survival of 7 mo without 
specific treatment[5]. Although peritoneal metastases 
develop avascular tumor nodules within the abdominal 
cavity that often cannot be efficiently addressed by 
systemic chemotherapy[6], advances in the development 
of cytostatic agents, targeted therapy and combined 
treatment regimens has led to significant improvement 
in survival rates. Moreover, additive treatment options 
such as cytoreductive surgery (CRS) and hyperthermic 
intraperitoneal chemotherapy (HIPEC) might be per-
formed with curative intent in selected patients[7]. Thus, 
pmCRC currently requires a multidisciplinary treatment 
approach that considers the available treatment options 
and modalities (Figure 1).
STAGING SYSTEMS FOR PM
The estimation of the extent of peritoneal tumor disse-
mination plays an important role in choosing thera-
peutic options for patients with pmCRC. Different 
staging systems allow for the standardization of PM 
classification and facilitate prognosis estimation. The 
most commonly used classification system for peritoneal 
tumor dissemination is the peritoneal cancer index 
(PCI). This numerical score combines the lesion size (LS) 
and tumor localization in 13 abdomino-pelvic regions 
including four small bowel regions (region 0-12) and 
ranges from 0 to 39[8]. The PCI was initially introduced for 
intraoperative determination of the extent of peritoneal 
carcinomatosis but the extent can also be determined 
by staging laparoscopy or diagnostic imaging. Elias et 
al[9] showed that the PCI is easy to use and reproducible 
with high inter-surgeon concordance. Although the PCI 
is underestimated by computed tomography compared 
to intraoperative findings, the clinical impact of the 
inaccuracies of CT-PCI is modest[10]. Thus, the (CT-)PCI is 
a helpful tool to determine and communicate the extent 
of peritoneal disease and to select patients for different 
therapeutic options. Moreover, the PCI correlates with 
overall and progression-free survival in patients with pm 
CRC[11-14]. Nevertheless, the predictive value is limited 
with respect to PM and does not include other prognostic 
factors. Therefore, prognostic scores for patients with pm 
CRC have been developed. The Peritoneal Surface Disease 
Severity Score (PSDSS) is based on the following three 
important prognostic indicators: (1) clinical symptoms; 
(2) PCI; and (3) tumor histopathology. The PSDSS ranges 
from 2 to 22 and divides patients into four prognostic 
groups (stage Ⅰ = PSDSS 2-4, stage Ⅱ = PSDSS 4-7, 
stage Ⅲ = PSDSS 8-10 and stage Ⅳ = PSDSS > 10)[15]. 
Several retrospective analyses show a high correlation 
between PSDSS and the survival of patients with pmCRC. 
The score might be helpful for determining survival 
probability and resectability of peritoneal disease in the 
context of therapeutic decision-making[16-18]. Another 
recently developed prognostic score for patients with 
pmCRC is the Colorectal Peritoneal Score (COREP). COREP 
includes signet cell histology, hemoglobin, white blood cell 
count and the value and status of serum tumor markers 
and ranges from 0 to 18. The cut-off value for the poor-
prognosis group is COREP > 6. In the first published 
evaluation of 77 patients the predictive value of COREP for 
open/close-procedure, R1 resection and one-year survival 
was superior to that of PSDSS[19]. Based on the Japanese 
classification of pmCRC, which divides peritoneal tumor 
dissemination into four groups (P0: no PM, P1: local PM, 
P2: limited distant, PM and P3: extended distant PM)[20,21] 
Noura et al[22] proposed a new simple classification 
system that includes the colorectal liver metastases (CLM) 
status. Patients without CLM and local (P1) or limited 
distant PM (P2) are classified as Grade A and Grade B, 
respectively. Patients with extended distant PM and all 
patients with CLM have been defined as Grade C. Initial 
data shows significant stratification of the survival and 
R0 resection rates[22]. However, new scores considering 
different histological and clinical factors might be helpful 
for decision-making and allow for further improvement of 
the selection of appropriate therapeutic options within a 
multidisciplinary treatment approach. 
SYSTEMIC ChEMOThERAPY FOR pmCRC
Although there are multiple prospective randomized trials 
and retrospective analyses about systemic chemotherapy 
in patients with advanced stage and metastatic CRC, 
data regarding the subgroup of patients with pmCRC 
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are limited. Franko et al[23] analyzed 364 patients with 
PM out of 2095 patients enrolled in the two prospective 
randomized NCCTG phase Ⅲ trials N9741 and N9841 
and showed a 30% relative reduction in overall survival 
in this subgroup. The 5-year OS rates were 4.1% and 6% 
and the median survival was 12.7 mo and 17.6 mo in 
the pmCRC and the non-pmCRC group, respectively. In 
this analysis infusional oxaliplatin-based chemotherapy 
was superior to irinotecan-based regimens irrespective of 
the PM status[23]. The subgroup analysis of patients with 
pmCRC enrolled in the prospective randomized CAIRO 
and CAIRO2 trials showed a significant impairment in 
the overall survival of these patients. Klaver et al[24] 
published a median OS of 10.4 and 17.3 mo in the 
CAIRO trial and 15.2 and 20.7 mo in the CAIRO2 
trial. An Asian prospective single-arm phase Ⅱ study 
investigating FOLFOX-4 in patients with pmCRC reported 
median overall survival of 21.5 mo. The median time 
to progression was 4.4 mo[25]. Consistent with these 
reported survival rates, Elias et al[26] reported a median 
OS of 23.9 mo under modern multidrug systemic chemo-
therapy in 48 patients with pmCRC from the French 
registry.
Considering the promising results of the first line 
treatment of patients with metastatic colorectal cancer 
using systemic polychemotherapy plus targeted therapy 
with median OS ranging from 25 mo to 41.3 mo[27-30] 
these regimens have also been used for treating pmCRC. 
In a retrospective analysis of 65 consecutive patients 
with pmCRC, Adachi et al[31] reported an improvement in 
the survival rate in response to systemic chemotherapy 
after incomplete cytoreduction. The oxaliplatin-based 
regimen and addition of targeted therapy was superior 
to irinotecan-based chemotherapy[31]. Razenberg et al[32] 
analyzed 1235 patients treated with palliative systemic 
chemotherapy for pmCRC. In 436 patients (35%) 
bevacizumab has been added to the treatment regimen. 
The median OS was 7.5 mo vs 11 mo in the bevacizumab 
group[32]. In a population-based study patients with 
metachronous colorectal PM were analyzed with respect to 
their treatment as follows: 94 patients received palliative 
systemic chemotherapy, 36 patients had the addition 
of bevacizumab and 92 did not receive therapy and 
the median survival was 13 mo, 20.3 mo and 3.4 mo, 
respectively[33]. Comparable results are reported by van 
Oudheusden in 82 patients who underwent open/close 
procedures for unresectable colorectal PM. The median OS 
was 11.2 mo with palliative systemic chemotherapy and 
2.7 mo with best supportive care[34].
These data demonstrate the efficacy of modern 
systemic chemotherapy regimens with or without targ-
eted therapy in improving the survival of patients with 
unresectable pmCRC. Based on these findings systemic 
chemotherapy should be considered the standard of care 
in patients with unresectable pmCRC and should be the 
backbone of a multimodal treatment regimen in patients 
who qualify for a multidisciplinary therapeutic approach. 
In the absence of contraindications, infusional oxali-
platinbased regimens, such as FOLFOX with or without 
monoclonal antibodies like bevacizumab, cetuximab or 
panitumumab, might be preferred as first-line therapies 
for these patients. Moreover, based on the results of the 
RAISE trial, ramucirumab might also be considered for 
the second-line treatment of patients with pmCRC[35]. 
Nevertheless, reliable data for this subgroup are not 
available.
SURGERY FOR pmCRC
CRS
In contrast to palliative surgery, such as fecal diversion, 
intestinal bypass, primary tumor resection, etc., CRS 
followed by HIPEC provides an additive treatment option 
for selected colorectal PM patients with a curative intent. 
Although disease recurrence is common[36], cure rates 
between 16% and 28% are reported after complete 
CRS and HIPEC[37,38]. The aim of surgical cytoreduction, 
which may consist of multiple peritonectomy procedures 
and visceral resections is the removal of all visible tumor 
deposits within the abdominal cavity[8,39,40]. Despite 
extensive and aggressive surgery, most patients return 
to baseline in terms of their quality of life within 6 mo 
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Figure 1  Proposed algorithm for treating peritoneal metastatic 
colorectal cancer. CC: Completeness of cytoreduction; CC-0/1: 
Complete macroscopic cytoreduction; IPC: Intraperitoneal 
chemotherapy; NIPS: Neoadjuvant intraperitoneal/systemic 
chemotherapy; PIPAC: Pressurized intraperitoneal aerosol 
chemotherapy; sCTx: Systemic chemotherapy; scattered lines 
indicate additional therapeutic options; HIPEC: Hyperthermic 
intraperitoneal chemotherapy.
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with high PCI should be avoided because of the impaired 
clinical and oncological outcomes. Moreover, there are 
no reliable data on patients with pmCRC and additional 
isolated resectable lung metastases. Therefore, lung 
metastasis should be considered a contraindication of 
CRS and HIPEC.
HIPEC
The aim of intraoperative HIPEC is to consolidate com-
plete surgical resection by destroying scattered (and 
residual) tumor cells within the abdominal cavity. In a 
prospective randomized phase Ⅲ trial comparing CRS 
and HIPEC plus systemic chemotherapy with 5-FU/FA to 
systemic chemotherapy with 5-FU/FA in selected patients 
with pmCRC there was a significant survival benefit for 
the treatment group. The median survival was 22 and 
12.6 mo for the treatment and non-treatment groups. 
In the subgroup of patients with complete macroscopic 
cytoreduction (CC-0/1), the median survival reached 
42.9 mo. The low survival rates might be explained by 
the use of 5-FU-based systemic chemotherapy in both 
groups in the pre-oxaliplatin era[53,54]. 
Elias et al[26] reported a median survival of 62.7 mo 
and a 5-year survival rate of 51% after complete ma-
croscopic cytoreduction and bidirectional oxaliplatin-
based HIPEC. All patients additionally received modern 
systemic chemotherapy[26]. A prospective phase Ⅱ study 
investigating complete macroscopic cytoreduction and 
bidirectional oxaliplatin-based HIPEC showed a 2-year 
overall survival rate of 88.7% and a median disease-free 
survival (DFS) of 19.8 mo[12]. Based on the promising 
results of the FOLFOXIRI protocol in the systemic 
treatment of mCRC, irinotecan has been added to the 
bidirectional oxaliplatin-based HIPEC regimen, leading 
to increased morbidity without improving the survival. 
Quenet et al[55] reported a median overall survival of 47 
mo and a 5-year survival rate of 42.4%. Goéré et al[37] 
reported a cure rate, defined as the 5-year disease-
free survival, of 16% after CRS and HIPEC in 107 
patients with pmCRC. Another retrospective analysis of 
342 patients with pmCRC from a prospective database 
showed a 10-year recurrence-free survival rate of 10% 
after CRS and HIPEC[56].
Although there are only few prospective RCTs, several 
studies and retrospective analyses show that the inte-
gration of CRS and HIPEC into a multidisciplinary treat-
ment approach that includes systemic chemotherapy can 
improve the survival of selected patients with pmCRC[7,57]. 
Nevertheless, the exact role of the HIPEC procedure and 
components remains unclear. A comparative analysis 
published by Hompes et al[58] investigated different HIPEC 
regimens and their effects on patient survival. There was 
no statistically significant difference between bidirectional 
oxaliplatin-based HIPEC and MMC-based HIPEC after 
complete macroscopic cytoreduction. The median RFS 
was 12.2 mo in the oxaliplatin-group and 13.8 mo in 
the MMC group (p = 0.87). The median OS was 37.1 
mo in the oxaliplatin group and 26.5 mo in the MMC 
after surgery[41-43]. The success of surgery is classified 
according to the completeness of cytoreduction (CC) 
score[13,44]. Complete macroscopic cytoreduction (CC-0/1), 
defined as no visible tumor or single tumor nodules < 
2.5 mm, is a precondition for the efficient application 
of HIPEC. Therefore, consistent preoperative patient 
selection is crucial for the efficacy of the multimodal 
treatment concept. A PCI > 20 might be considered a 
relative contraindication for CRS and HIPEC[45]. Da Silva 
et al[11] reported a median OS of 41 mo in patients with 
PCI < 20 and 16 mo in patients with PCI > 20 after 
complete macroscopic cytoreduction. Comparable results 
are published by Hompes et al[12] for patients with a PCI 
higher or lower than 15. A recently published analysis of 
180 patients defined a cut-off PCI value of 17[14]. 
CRS in patients with additional CLM
There are limited published data regarding cytoreductive 
surgery in patients with additional resectable CLM. In 
a retrospective matched-pair analysis, hepatobiliary 
procedures during CRS and HIPEC did not lead to in-
creased perioperative complication rates and/or overall 
mortality[46]. According to the Milan consensus statement 
of the Peritoneal Surface Malignancy Group International 
cytoreductive surgery (and HIPEC) should not be 
routinely recommended in patients with more than three 
peripheral resectable liver metastases[45]. However, two 
retrospective studies demonstrated median survival 
rates of approximately 36 mo after CRS, including 
mostly minor liver resections followed by HIPEC[47,48]. As 
expected, liver involvement is associated with decreased 
overall survival rates. Berger et al[49] reported a median 
overall survival of 45.1 mo in 108 patients with additional 
liver involvement and 73.5 mo in 166 patients with 
isolated PM after CRS and HIPEC. Nevertheless, patients 
with malignancies other than CRC were included in the 
analysis. There was no significant difference regarding 
the morbidity and mortality between the two groups[49]. 
Allard et al[50] reported a median survival of 42 mo in 
patients who underwent complete resection of CLM 
and unexpected limited CPM with a median PCI of 2. 
In a multivariate analysis Delhorme et al[51] identified 
the size of liver metastasis and grade Ⅱ/Ⅲ toxicity of 
preoperative chemotherapy as poor prognostic factors. 
Response to preoperative chemotherapy significantly 
increased overall survival. These data are supported 
by a recently published meta-analysis that identified 
concurrent CLM as an independent negative prognostic 
factor for overall survival in patients with pmCRC after 
CRS and HIPEC[52]. Noura et al[22] showed that the 
presence of CLM impairs survival and R0 resection rates. 
The 5-year overall survival rates of patients without CLM 
and local or limited distant PM were 25.6% and 12.0%, 
respectively. The 5-year survival rate of patients with 
extended distant PM and/or additional CLM was 5.6%. 
R0 resection rates were 65.9%, 44.6% and 8.1%[22]. 
However, the combination of extended liver surgery for 
CLM and extended cytoreductive surgery in patients 
Glockzin G et al . Peritoneal metastasis from colorectal cancer
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trial evaluates the effect of adjuvant HIPEC during or 
shortly after resection of primary CRC with a high risk of 
metachronous PM. A risk reduction from 25% to 10% 
and, therefore, improvement in the long-term survival is 
assumed[66]. 
HIPEC without cytoreductive surgery, also applied 
by the laparoscopic approach, might be considered in 
patients with unresectable PM (Figure 2) and symp-
tomatic therapy for refractory malignant ascites. Several 
retrospective studies showed significant reduction of 
ascites production and efficient symptom control after 
HIPEC. Nevertheless, the number of reported patients 
and procedures is limited and data from prospective 
randomized trials are not available[67-69].
PERIOPERATIvE SYSTEMIC 
ChEMOThERAPY
The importance of systemic chemotherapy in the context 
of CRS and HIPEC has been demonstrated. Postoperative 
systemic chemotherapy has been shown to be an inde-
pendent positive prognostic marker in all registries and 
retrospective analyses[13,70]. In a recently published 
database analysis of 5516 patients with PM arising from 
colorectal adenocarcinoma, mucinous adenocarcinoma 
and signet ring cell carcinoma, Simkens et al[71] sho-
wed that systemic chemotherapy improved survival 
independent of the histological subtype. In contrast to 
these findings, a multicenter study, including 221 patients 
with pmCRC reported no significant difference in the OS 
after CRS and HIPEC between postoperative systemic 
chemotherapy and surveillance. The median OS was 
43.3 mo. Nevertheless, during the first year the rates 
of progression and recurrence were significantly lower 
in the chemotherapy group[72]. However, the optimal 
sequence of the therapeutic modalities remains a matter 
of investigation. Elias et al[13] reported no significant 
impact on the prognosis of neoadjuvant systemic chemo-
therapy in patients undergoing CRS and HIPEC for 
pmCRC. Passot et al[73] showed an overall response rate 
of 36% and a disease progression rate of 21% in patients 
who received different regimens of modern neoadjuvant 
systemic chemotherapy before CRS and HIPEC. 
Interestingly, the response to neoadjuvant treatment 
was not a significant prognostic factor, therefore, it might 
not be considered a contraindication for CRS and HIPEC. 
The median survival of patients with disease progression 
was 31.4 mo[73]. Further analysis of different preoperative 
chemotherapy regimens consisting of 5-FU, oxaliplatin, 
irinotecan and/or monoclonal antibodies showed a 9.7% 
complete response rate, 20.2% major response and 
70.1% rate of minor or no response. In the multivariate 
analysis the pathohistological response was an 
independent predictor of survival (p = 0.01)[74]. Devilee 
et al[75] compared patients with pmCRC who received 
neoadjuvant systemic chemotherapy before CRS and 
HIPEC with patients who were treated with adjuvant 
group (p = 0.45)[58]. A matched-pair analysis showed 
no significant differences in morbidity and mortality by 
HIPEC regimen. The grade 3/4 morbidity rates according 
to CTCAE were 42.5% in the OX group and 37.5% in the 
MMC group (p = 0.648) and the mortality rates of the 
OX and MMC groups were 2.5% and 0%, respectively[59]. 
Consistent with these findings the American Society of 
Peritoneal Surface Malignancies reported an OS of 32.7 
mo in patients with MMC-based HIPEC and 31.4 mo for 
oxaliplatin-based HIPEC in 539 patients with pm CRC 
after complete macroscopic cytoreduction (p = 0.925). 
After stratification to PSDSS there was a statistically 
significant survival benefit for the MMC-subgroup with 
PSDSS Ⅰ/Ⅱ (p = 0.012)[60]. A retrospective analysis 
of a limited number of patients compared bidirectional 
oxaliplatin-based HIPEC to bidirectional irinotecan-based 
HIPEC. The 3-year survival rates were 65.0% in the OX 
group vs 41.7% in the IRI group (p = 0.295)[61]. 
In a recently published retrospective analysis of 50 
consecutive patients with pmCRC, Désolneux et al[62] 
reported a median survival of 34.2 mo and a 5-year 
survival rate of 29.6% after complete macroscopic 
cytoreduction and systemic chemotherapy alone. These 
findings are supported by a retrospective Japanese 
multicenter database analysis of 564 patients who 
underwent surgery without HIPEC for pmCRC. In patients 
with R0 resection, the median overall survival was 30 mo 
and 5-year survival rate was 32.4%. The 5-year survival 
rate after R0 resection and adjuvant chemotherapy 
was 31.7% compared to 24.6% without adjuvant 
treatment. R0 resection and adjuvant chemotherapy were 
independent positive prognostic factors for survival[63]. 
This concept and the role of HIPEC is investigated by 
the French prospective randomized PRODIGE 7 trial that 
compares CRS and HIPEC plus systemic chemotherapy 
with CRS alone plus systemic chemotherapy. However, 
survival data are not yet available. Cashin et al[64] 
published survival data of a prematurely terminated 
prospective randomized trial evaluating CRS followed 
by normothermic intraperitoneal chemotherapy (IPC) 
with 5-FU vs CRS followed by systemic oxaliplatin-based 
chemotherapy. Both treatments were continued for 6 mo. 
The median overall survival times were 25 mo vs 18 mo (p 
= 0.04) and the 2-year survival rates were 54% vs 38% (p 
= 0.04)[64]. However, the optimal therapeutic regimen of 
IPC after complete CRS remains a matter of debate[65].
Prophylactic and palliative HIPEC
Another therapeutic concept that is evaluated by the 
ongoing French ProphyloCHIP trial is the prophylactic 
application of HIPEC in patients with CRC and high risk 
of developing PM, such as tumor perforation, isolated 
ovarian metastases or removal of localized PM during 
resection of primary tumor resection. The enrolled 
patients were randomized eight months after adjuvant 
chemotherapy to the control arm with follow-up or to 
the treatment arm with explorative laparotomy and 
prophylactic HIPEC (NCT01226394). The COLOPEC 
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chemotherapy (NIPS) for gastric cancer. Clinical trials are 
needed to evaluate the potential role of IPC in patients 
with pmCRC, especially in the neoadjuvant setting. 
Preoperative IPC or NIPS may allow for higher rates of 
CC-0/1 resection and may further improve the outcome 
after CRS and HIPEC. Moreover, sequential IPC with or 
without palliative systemic chemotherapy might improve 
response rates and local tumor control in patients with 
unresectable PM arising from CRC.
Pressurized intraperitoneal aerosol chemotherapy 
(PIPAC) is a new technique for the local application of 
cytostatics as aerosol under pressure that allows for 
improved drug distribution and tumor tissue penetration. 
The feasibility and safety of the procedure has been 
demosntrated[82,83]. Most data published for ovarian 
cancer show local anticancer activity after sequential 
application of PIPAC[84]. A recently published retrospective 
analysis of 48 applications of PIPAC given every six 
weeks in 17 patients with pretreated pmCRC reported 
a median OS of 15.7 mo. The overall response rate was 
71%[85]. Quality of life analysis accessed by the EORTC-
QLQ30 questionnaire in 48 patients with PM arising from 
different tumor entities (PCI: 16 ± 10) that received at 
least two PIPAC applications showed an impairment of 
the global physical score and pain score after the first 
treatment improved after the second PIPAC application. 
Gastrointestinal symptoms remained stable with PIPAC 
therapy[86]. Based on the promising preliminary data, 
PIPAC might become an additional therapeutic option 
for the palliative local treatment of pmCRC in the future. 
Moreover, it might be interesting as a neoadjuvant 
local treatment with or without the addition of systemic 
chemotherapy beyond CRS and HIPEC. Several pro-
spective clinical trials evaluating this therapy approach 
are ongoing. The results may help to determine the role 
of PIPAC within a multidisciplinary treatment concept and 
allow for further improvement of patient selection.
CONClUSION
The therapeutic approach to PM of colorectal cancer has 
changed in recent decades. There are multiple treatment 
options for patients with pmCRC that must be integrated 
in an individualized multidisciplinary treatment approach 
(Figure 1). Consistent diagnostics and patient selection 
are crucial to obtaining optimal oncologic outcome. Thus, 
the therapeutic approach should be discussed by an 
interdisciplinary tumor board, and, if necessary, patients 
should be referred to specialized treatment centers. In 
addition to multiple palliative treatment options, CRS 
and HIPEC provide an additive treatment modality with 
curative intent for selected patients with pmCRC. The 
integration of further treatment options such as repeated 
preoperative intraperitoneal chemotherapy or PIPAC 
in current treatment regimens should be discussed 
and evaluated in randomized controlled clinical trials. 
Prognostic factors, such as peritoneal tumor distribution, 
lymph node status, hematogenous metastasis, histology, 
tumor mutation status, tumor immunology, numerous 
systemic chemotherapy after CRS and HIPEC. All patients 
underwent complete or nearly complete macroscopic 
cytoreduction. The 3-year survival rates were 89% and 
50% for the neoadjuvant and adjuvant groups. Although 
the PCI was lower and operation time was shorter for 
patients who received preoperative chemotherapy, 
neoadjuvant treatment was still independently associated 
with improved survival after correcting for other 
significant prognostic factors[75]. Kuijpers et al[76] analyzed 
a prospective database regarding the effect of systemic 
chemotherapy on survival of patients with lymph-node 
positive pm CRC undergoing CRS and HIPEC. There was 
a statistically significant increase in the median PFS (15 
mo vs 4 mo, p = 0.024) and median OS (30 mo vs 14 
mo, p = 0.015) in patients who received perioperative 
systemic chemotherapy. Interestingly, the timing of 
systemic chemotherapy had no influence on survival[76]. 
The prospective multicenter phase Ⅱ COMBATAC 
study evaluates CRS and bidirectional oxaliplatin-
based HIPEC plus perioperative cetuximab-containing 
polychemotherapy[77]. The first safety data showed no 
increase in the morbidity or mortality when using the 
perioperative treatment approach[78]. There is another 
ongoing prospective phase Ⅱ study (BEV-IP) evaluating 
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patient-related factors and the resection status must be 
considered during patient selection and should be further 
investigated. The development and clinical use of the 
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regimens that consider all available therapeutic options. 
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with pmCRC are highly recommended to optimize and 
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